Evidence map›Paper›PMID 31166991›Full record

ArticlePloS one2019

Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients.

Keisuke Taniuchi, Mutsuo Furihata, Seiji Naganuma, Masahiko Sakaguchi, Toshiji Saibara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Structure and molecular function of the BCL7 proteins.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Landmarks in pancreatic cancer studies.Cancer cell international · 2022
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. International journal of molecular sciences · 2021
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Keisuke TaniuchiDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.ORCID 0000-0001-9165-7494
Mutsuo FurihataDepartment of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Seiji NaganumaDepartment of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Masahiko SakaguchiIntegrated Center for Advanced Medical Technologies, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Toshiji SaibaraDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Kōchi University · JPKanagawa Prefectural Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that overexpression of PODXL, BCL7B, and ARHGEF4 in pancreatic cancer tissue is correlated with pancreatic cancer-related survival. The aim of this study was to investigate the use of PODXL, BCL7B, ARHGEF4, and the integrin family member ITGB1 as useful markers for the prognosis of postoperative pancreatic cancer patients in comparison with tumor size and the tumor node metastasis (TNM) staging system. Immunohistochemistry was performed using an anti-ITGB1 antibody on 102 samples of pancreatic cancer tissue surgically resected at the University of Kochi Medical School Hospital and the Matsuyama Shimin Hospital. Univariate Cox proportional hazards regression analysis showed that TNM stage and overexpression of PODXL, BCL7B, and ITGB1 were correlated with postoperative survival. However, tumor size was not significantly associated with postoperative prognosis of pancreatic cancer compared to these features. Multivariate Cox proportional hazards regression analysis showed that the overexpression of both PODXL and ITGB1 and overexpression of both BCL7B and ITGB1 increased the hazard ratio (6.27, 95% confidence interval [CI] 2.58-15.21; and 3.93, 95% CI 1.74-8.91, respectively) compared to that of TNM stage (IIA and IIB vs. III and IV; 3.05, 95% CI 1.25-7.42). These results imply that the combination of PODXL with ITGB1 and the combination of BCL7B with ITGB1 accurately predicted the postoperative outcomes of pancreatic cancer patients, and they were superior compared to the TNM staging system. The combination of PODXL with ITGB1 would be particularly useful, as it was the most highly correlated with postoperative outcomes. Importantly, the present results are useful to determine which adjuvant therapy should be selected.

Indexed as

AdultAgedAged, 80 and overFemaleHumansIntegrin beta1Kaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPancreatic NeoplasmsPostoperative PeriodPrognosisProportional Hazards ModelsProteinsARHGEF4 protein, humanBCL7B protein, humanIntegrin beta1podocalyxinProteinsRho Guanine Nucleotide Exchange FactorsSialoglycoproteins

Identifiers

PMID31166991
PMCPMC6550449
OpenAlexW2948161876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.